checkAd

    DGAP-News  800  0 Kommentare MOLOGEN AG: Oliver Krautscheid reelected as Chairman of the Supervisory Board (news with additional features)


    DGAP-News: MOLOGEN AG / Key word(s): AGM/EGM
    MOLOGEN AG: Oliver Krautscheid reelected as Chairman of the
    Supervisory Board (news with additional features)

    30.07.2015 / 16:55

    ---------------------------------------------------------------------

    PRESS RELEASE N 12 / 2015 of 07/30/2015

    MOLOGEN AG: Oliver Krautscheid reelected as Chairman of the Supervisory
    Board

    Berlin, July 30, 2015 - At yesterday's Annual General Meeting of the
    biotechnology company MOLOGEN AG, Oliver Krautscheid was reelected as a
    member of the Supervisory Board. In addition, the Supervisory Board once
    again unanimously voted Oliver Krautscheid to the position of Chairman of
    the Supervisory Board. Stefan M. Manth, MD, will remain in the role of Vice
    Chairman. The shareholders also approved the main items on the agenda.

    The voting results and further information on the Annual General Meeting
    can be found on the company website under:
    http://www.mologen.com/en/investor-relations-press/annual-general-meeting.
    html

    MOLOGEN AG
    MOLOGEN AG is a biotechnology company specialized in the research and
    clinical development of cancer immunotherapies and DNA vaccines against
    infectious diseases.

    The cancer immunotherapy MGN1703 is the company's lead product and
    best-in-class TLR9 agonist. It is currently developed for first-line
    maintenance treatment of colorectal cancer (pivotal randomized trial) and
    small cell lung cancer (randomized controlled trial). A second
    clinical-stage product is MGN1601, a therapeutic vaccination for the
    treatment of renal cancer. A phase I/II clinical study has already been
    completed successfully.

    For more information on the trials please visit www.clinicaltrials.gov.

    With unique, patented technologies and innovative products, MOLOGEN is
    pioneering immuno- therapies.

    MOLOGEN AG is a publicly listed company, headquartered in Berlin. The
    shares (ISIN DE0006637200) are listed in the Prime Standard of the German
    Stock Exchange.

    www.mologen.com

    Memberships in associations:
    Biotechnologieverbund Berlin-Brandenburg (bbb) e.V. | BIO Deutschland e.V.
    | DECHEMA - Society for chemical technology and biotechnology e.V. |
    German industrial association of biotechnology (DIB) | Association for
    the Promotion of Science and Humanities in Germany | Association of
    German biotechnology companies (VBU) | Association of researching
    manufacturers of pharmaceuticals e.V. (VFA) | Association of the chemical
    industry e.V. (VCI)

    MIDGE(R), dSLIM(R), EnanDIM(R) and MOLOGEN(R) are registered trademarks of
    MOLOGEN AG.

    Contact
    Claudia Nickolaus
    Head of Investor Relations & Corporate Communications
    Tel: +49 - 30 - 84 17 88 - 38
    Fax: +49 - 30 - 84 17 88 - 50
    investor@mologen.com

    Note about risk for future predictions
    Certain information in this report contains forward-looking statements or
    the corresponding statements with negation or versions deviating from this
    or comparable terminology. These are described as forward-looking
    statements. In addition, all of the information given here that refers to
    planned or future results of business areas, key financial figures,
    developments of the financial situation or other financial figures or
    statistical data, is to be understood as such forward-looking statements.
    The company points out to investors that they should not rely on these
    forward-looking statements as predictions about actual future events. The
    company is not obligated and refuses to accept any liability for the
    forward-looking statements and has no obligation to update such statements
    in order to accurately reflect the current situation.



    +++++
    Additional features:

    Document: http://n.equitystory.com/c/fncls.ssp?u=HYUSYIOLIJ
    Document title: MOLOGEN AG: Oliver Krautscheid reelected as Chairman
    of the Supervisory Board

    ---------------------------------------------------------------------

    30.07.2015 Dissemination of a Corporate News, transmitted by DGAP - a
    service of EQS Group AG.
    The issuer is solely responsible for the content of this announcement.

    The DGAP Distribution Services include Regulatory Announcements,
    Financial/Corporate News and Press Releases.
    Media archive at www.dgap-medientreff.de and www.dgap.de

    ---------------------------------------------------------------------


    Language: English
    Company: MOLOGEN AG
    Fabeckstraße 30
    14195 Berlin
    Germany
    Phone: 030 / 841788-0
    Fax: 030 / 841788-50
    E-mail: presse@mologen.com
    Internet: www.mologen.com
    ISIN: DE0006637200
    WKN: 663720
    Listed: Regulated Market in Frankfurt (Prime Standard); Regulated
    Unofficial Market in Berlin, Dusseldorf, Hamburg, Munich,
    Stuttgart


    End of News DGAP News-Service
    ---------------------------------------------------------------------
    382487 30.07.2015


    Diskutieren Sie über die enthaltenen Werte


    EQS Group AG
    0 Follower
    Autor folgen

    Verfasst von EQS Group AG
    DGAP-News MOLOGEN AG: Oliver Krautscheid reelected as Chairman of the Supervisory Board (news with additional features) DGAP-News: MOLOGEN AG / Key word(s): AGM/EGM MOLOGEN AG: Oliver Krautscheid reelected as Chairman of the Supervisory Board (news with additional features) 30.07.2015 / 16:55 --------------------------------------------------------------------- PRESS …